Perinatal PM2.5 Exposure Varies by Race and Ethnicity but Does Not Mediate Disparities in Infant Cardiac Surgery Outcomes: A Causal Mediation Analysis
Abstract Body (Do not enter title and authors here): Introduction: Racial and ethnic disparities in congenital heart surgery outcomes are well documented and attributed to social determinants, but the full range of contributing factors remains unclear. Chronic exposure to particulate matter ≤2.5 µm diameter (PM2.5) is linked to adverse outcomes in adults. Given that minority communities are exposed to higher PM2.5 levels, we investigated how perinatal PM2.5 exposure mediates the relationship between race/ethnicity and infant congenital heart surgery outcomes.
Hypothesis: Perinatal exposure to PM2.5 may be in the causal pathway between race/ethnicity and the days alive and out of healthcare (DAoH) among infants undergoing cardiac surgery (Image 1).
Methods: We linked clinical registry data from the New York State (NYS) Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources with Medicaid claims and census tract-level daily PM2.5 concentrations from 2006-2017. Race/ethnicity was categorized as Hispanic, Non-Hispanic (NH) Asian, NH-Black, and NH-White. Our outcome was DAoH during the first two years of life (as % of 730 days). Mediator candidates included average exposure to PM2.5 during gestational weeks 0-8, 0-35, and postnatal period ages 0-1 and 0-2 years. We applied fractional logit and linear regression for each mediator, adjusting for clinical factors and surgical center, within a causal mediation framework. Analyses were then stratified by urbanicity.
Results: Our cohort included 2,505 infants (33% Hispanic, 11% NH-Asian, 22% NH-Black, and 35% NH-White). Adjusted mean DAoH was 79.6% (95% CI 68.3-86.3) for Hispanic, 84.5% (70.3-87.3) for NH-Asian, 77.4% (66.6-86.4) for NH-Black, and 81.7% (70.0-86.3) for NH-White. In urban settings, NH-Black children experienced higher levels of PM2.5 (µg/m3) compared to NH-White children (0.44 µg/m3 [CI 0.25-0.64] at 0-35 gestational weeks, 0.44µg/m3[CI 0.27-0.61] age 0-1 year, and 0.32 µg/m3 [CI 0.16-0.48] age 0-2 years). PM2.5 exposure was not significantly associated with DAoH. Mediation analyses revealed no significant indirect effect.
Conclusion: While differences in perinatal exposure to PM2.5 were observed by race/ethnicity among infants living in urban areas, our findings suggest that this environmental factor does not mediate racial and ethnic disparities in outcomes after congenital heart surgery in NYS. This highlights the need to explore other determinants of postoperative disparities in pediatric cardiac care.
Ramadurai, Saranya
( Mount Sinai Hospital
, New York
, New York
, United States
)
Linder, Alexandra
( CHILDRENS HOSPITAL BOSTON
, Boston
, Massachusetts
, United States
)
Mosca, Ralph
( NYU Medical Center
, New York
, New York
, United States
)
Kumar, Tk
( NYU Langone Health
, New York City
, New York
, United States
)
Devejian, Neil
( Albany Medical Center
, Glenmont
, New York
, United States
)
Kamenir, Steven
( Albany Medical Center
, Slingerlands
, New York
, United States
)
Alfieris, George
( University of Rochester
, Rochester
, New York
, United States
)
Swartz, Michael
( UNIVERSITY OF ROCHESTER
, Rochester
, New York
, United States
)
Meyer, David
( Northwell Medical Center
, Uniondale
, New York
, United States
)
Woo, Joyce
( Lurie Children's, Northwestern U
, Chicago
, Illinois
, United States
)
Graber, Nathan
( New York Department of Health
, New York
, New York
, United States
)
Zhou, Eric
( Mount Sinai Hospital
, New York
, New York
, United States
)
Sheffield, Perry
( Mount Sinai Hospital
, New York
, New York
, United States
)
Anderson, Brett
( Icahn School of Medicine
, New York
, New York
, United States
)
Crook, Sarah
( Mount Sinai Hospital
, New York
, New York
, United States
)
Sanchez, Chantal
( Mount Sinai Hospital
, New York
, New York
, United States
)
Goldstone, Andrew
( Columbia University Medical Center
, New York
, New York
, United States
)
Billings, John
( New York University
, New York
, New York
, United States
)
Newburger, Jane
( CHILDRENS HOSPITAL BOSTON
, Boston
, Massachusetts
, United States
)
Jacobs, Marshall
( Johns Hopkins Medical Institution
, Baltimore
, Maryland
, United States
)
Ebstein, Rebecca
( Cornell Medical Center
, New York
, New York
, United States
)
Author Disclosures:
Saranya Ramadurai:DO NOT have relevant financial relationships
| Alexandra Linder:No Answer
| Ralph Mosca:No Answer
| TK Kumar:DO NOT have relevant financial relationships
| Neil Devejian:No Answer
| Steven Kamenir:No Answer
| George Alfieris:No Answer
| Michael Swartz:DO NOT have relevant financial relationships
| David Meyer:No Answer
| Joyce Woo:DO NOT have relevant financial relationships
| Nathan Graber:No Answer
| Eric Zhou:No Answer
| Perry Sheffield:DO NOT have relevant financial relationships
| Brett Anderson:DO have relevant financial relationships
;
Researcher:Autus, Inc.:Active (exists now)
| Sarah Crook:DO NOT have relevant financial relationships
| Chantal Sanchez:No Answer
| Andrew Goldstone:No Answer
| John Billings:No Answer
| Jane Newburger:DO have relevant financial relationships
;
Research Funding (PI or named investigator):PFizer:Active (exists now)
; Other (please indicate in the box next to the company name):Bristol-Myer-Squibb- DSMB Co-Chair for trial on pediatric mavacamten:Active (exists now)
; Research Funding (PI or named investigator):Bristol-Myer-Squibb- Chair, Independent Events Adjudication Committee for Pediatric Apixaban trials:Past (completed)
; Research Funding (PI or named investigator):Pfizer- Chair, Independent Events Adjudication Committee for pediatric apixaban trials:Past (completed)
| Marshall Jacobs:No Answer
| Rebecca Ebstein:No Answer